N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
Phase 2 N=81 Medications for Stopping Cocaine Dependence and Preventing Relapse
Cocaine Abuse · Cocaine-Related Disorders
Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines
Phase 2 N=66 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Cannabis Dependence · Cannabis Withdrawal
Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…
Phase 2 N=150 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence · Cannabis Withdrawal · Cognitive Deficits
Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…
Phase 2 N=50 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029
Phase 2 N=10 Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC) — 2.67; 0.83; -0.33; -0.17 units on…
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 2 N=15 Study of Quetiapine Treatment for Cannabis Dependence
Cannabis Dependence
Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams
Phase 3 N=123 A Physical Dependence Study in Schizophrenia
Schizophrenia
Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Phase 2 N=150 Gabapentin Treatment of Alcohol Dependence
Alcoholism · Alcohol Dependence
Primary: Drinking — 6; 8; 2 participants — p=<0.04
N/A N=321 Effectiveness of Extended Treatments for Drug Dependence
Cocaine Dependence
Primary: Abstinence — 45; 57; 45 participants
Phase 2 N=108 New Medication Treatment for Stimulant Dependence
Cocaine Dependence
Primary: Cocaine Use by Self-report — 67; 67 Percent of cocaine-free (abstinent)days — p=0.972
Phase 2 N=42 Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue (30 Minutes), and From Test Day 1 Through Test Day 4 (1 Week)) - Via the Visual Analog Scale for…
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
Phase 3 N=52 Nabilone for Cannabis Dependence: A Pilot Study
Cannabis Dependence · Marijuana Dependence
Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio
Phase 2 N=130 Quetiapine Pharmacotherapy for Cannabis Dependence
Cannabis Dependence
Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars
N/A N=40 Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Phase 2 N=12 Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
Cannabis Dependence
Primary: Change in Marijuana Use — -1.7 days
Phase 3 N=122 Combined Pharmacotherapy for Cannabis Dependency
Cannabis Dependence · Marijuana Dependence
Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants
Phase 2 N=12 Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence
Cannabis Dependence · Nicotine Dependence
Primary: Cigarette Use — 12.6; 2.1 cigarettes/day
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Phase 1 N=22 Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence
Cannabis Dependence
Primary: Reduction in Mean Number of Days of Cannabis Use Per Week — 4.1; 3.1 days of use per week
Phase 2 N=76 Vilazodone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS
Phase 3 N=58 Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence
Tobacco Dependence · Nicotine Dependence
Primary: Fageström Test for Nicotine Dependence Score at Baseline and After 90 Days of the Treatment — 6.53; 6.56; 5.96; 5.22 units on a scale
Phase 3 N=60 Dronabinol Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) . — 11.16; 13.36 units on a scale